Cystic Fibrosis Market in Europe 2015-2019

欧州の嚢胞性線維症(CF症)治療薬市場

◆タイトル:Cystic Fibrosis Market in Europe 2015-2019
◆商品コード:IRTNTR5271
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年2月18日
◆ページ数:113
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:欧州
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥499,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、欧州の嚢胞性線維症(CF症)治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、欧州の嚢胞性線維症(CF症)治療薬市場規模及び予測、市場シェア、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Cystic Fibrosis
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.

TechNavio’s analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:

• Small Molecules
• Biologics

TechNavio’s report, Cystic Fibrosis Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Actavis
• F. Hoffmann-La Roche
• Gilead Sciences
• Novartis
• Vertex Pharmaceuticals

[Other Prominent Vendors]
• Abbott
• Anthera Pharmaceuticals
• Arcturus Therapeutics
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Corbus Pharmaceuticals
• Genzyme
• Insmed
• Johnson & Johnson
• Merck Sharp & Dohme
• Neovii Biotech
• Novo Nordisk
• PharmaSwiss
• Pharmaxis
• Proteostasis Therapeutics
• PTC Therapeutics
• United Medical
• Venus Remedies

[Market Driver]
• Unmet Needs
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Treatments
• For a full, detailed list, view our report

[Market Trend]
• Rise in Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1.1 Zenpep
05.1.2 Colomycin/Colobreathe
05.1.3 Pulmozyme
05.1.4 Cayston
05.1.5 TOBI/TOBI Podhaler
05.1.6 Kalydeco

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Pathophysiology
07.3 Epidemiology
07.3.1 Global
07.3.2 UK
07.4 Diagnosis
07.4.1 Carrier Testing
07.4.2 Antenatal Testing
07.4.3 Newborn Screening
07.4.4 Other Tests
07.5 Manifestations of Cystic Fibrosis
07.6 Economic Burden

08.Pipeline Portfolio

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
10.1 Biologics
10.1.1 Enzymes
10.2 Small Molecules
10.2.1 CFTR Modulators
10.2.2 Antibiotics

11.Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
11.1 Oral
11.2 Parenteral
11.3 Topical

12.Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
12.1 Solid
12.2 Liquid

13.Key Leading Countries
13.1 UK
13.2 France
13.3 Italy
13.4 Germany
13.5 Spain

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Actavis
21.2.2 F. Hoffmann-La Roche
21.2.3 Gilead Sciences
21.2.4 Novartis
21.2.5 Vertex Pharmaceuticals
21.3 Other and Future Prominent Vendors

22.Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Information
22.1.8 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.3 Gilead Sciences
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Geographical Segmentation by Revenue 2013
22.3.4 Recent Developments
22.3.5 SWOT Analysis
22.4 Novartis
22.4.1 Key Facts
22.4.2 Business Description
22.4.3 Business Segmentation
22.4.4 Revenue by Business Segmentation
22.4.5 Revenue Comparison 2012 and 2013
22.4.6 Sales by Geography
22.4.7 Business Strategy
22.4.8 Key Developments
22.4.9 SWOT Analysis
22.5 Vertex Pharmaceuticals
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue 2013
22.5.6 Business Strategy
22.5.7 Recent Developments
22.5.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Cystic Fibrosis
Exhibit 3: Defects Caused by CFTR Mutation
Exhibit 4: Prevalence Rate of Cystic Fibrosis by Country 2014
Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014 (million)
Exhibit 6: Forecast for Prevalence of Cystic Fibrosis in UK 2014-2019 (million)
Exhibit 7: Age Distribution of Cystic Fibrosis Patients in UK at Death 2013 (in years)
Exhibit 8: Age Distribution of Cystic Fibrosis Patients in UK by Gender 2013
Exhibit 9: Age Distribution of Cystic Fibrosis Patients in UK by Sex 2013
Exhibit 10: Diagnosis of Cystic Fibrosis
Exhibit 11: Manifestations of Cystic Fibrosis
Exhibit 12: Snapshot of Economic Burden of Cystic Fibrosis
Exhibit 13: Pipeline Snapshot of Cystic Fibrosis Drugs
Exhibit 14: Cystic Fibrosis Market in Europe 2014-2019 (US$ million)
Exhibit 15: Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
Exhibit 16: Cystic Fibrosis Market in Europe by Molecule Type 2014
Exhibit 17: Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
Exhibit 18: Cystic Fibrosis Market in Europe by Route of Administration 2014
Exhibit 19: Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
Exhibit 20: Cystic Fibrosis Market in Europe by Dosage Form 2014
Exhibit 21: Buying Criteria in Cystic Fibrosis Market in Europe
Exhibit 22: Drivers and their Impact on the Key Customer Category of the Cystic Fibrosis Market in Europe
Exhibit 23: Cystic Fibrosis Market in Europe Market Share Analysis 2014
Exhibit 24: Global Sales of Pulmozyme 2012 and 2013 (US$ million)
Exhibit 25: Quarterly Global Sales of Pulmozyme 1994-2008 (US$ million)
Exhibit 26: Quarterly Sales of Pulmozyme to Collaborators 1997-2008 (US$ million)
Exhibit 27: TOBI Podhaler
Exhibit 28: Comparison of YoY Global Sales of TOBI and TOBI Podhaler 2006-2013 (US$ million)
Exhibit 29: Comparison of YoY Global Sales of Kalydeco 2012-2013 (US$ million)
Exhibit 30: Cystic Fibrosis Market in Europe Business Segmentation 2013
Exhibit 31: Cystic Fibrosis Market in Europe Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 32: Actavis : Sales by Geography (in US$ million)
Exhibit 33: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 34: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 35: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 36: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 37: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 38: Novartis AG: Business Segmentation
Exhibit 39: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 40: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 41: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 42: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 43: Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 44: Vertex Pharmaceuticals: Geographical Segmentation by Revenue 2013



【掲載企業】

Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals , Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics , Boehringer Ingelheim , Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson ,Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss , Pharmaxis , Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies

【資料のキーワード】

嚢胞性線維症(CF症)、治療薬、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[欧州の嚢胞性線維症(CF症)治療薬市場] (Cystic Fibrosis Market in Europe 2015-2019 / IRTNTR5271)販売に関する免責事項
[欧州の嚢胞性線維症(CF症)治療薬市場] (Cystic Fibrosis Market in Europe 2015-2019 / IRTNTR5271)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆